The diagnostic test, developed by Biodesix, Inc, will help guide treatment decisions in patients with advanced lung cancer.
Biodesix, Inc, today announced that its VeriStrat test received a positive coverage decision from UnitedHealthcare, one of the largest commercial insurance companies in the US, with a published 44.7 million covered lives. In its Medical Policy, UnitedHealthcare describes VeriStrat as “…proven for guiding treatment decisions in patients with advanced non-small cell lung cancer (NSCLC).”
VeriStrat, included in the standard of care guidelines, is a blood-based proteomic test that provides physicians with prognostic and predictive information that helps guide treatment of advanced NSCLC. Patients with a VeriStrat Poor test result have a shorter median overall survival than those with a VeriStrat Good result. Understanding the patient’s disease state can help inform physicians’ decisions on chemotherapy, palliative care or clinical trials.
Read the complete news release on Yahoo!: http://yhoo.it/1HcbqFK